Can You Take Ritonavir and Sildenafil Together?

No, ritonavir and sildenafil should not be used together without strict medical supervision and dose adjustment. According to the FDA-approved sildenafil label, this combination is listed as contraindicated, meaning the risk generally outweighs the benefit. If a healthcare provider determines that the combination is necessary, the maximum single dose of sildenafil must not exceed 25 mg, and no more than one dose should be taken within a 48-hour period. This severe restriction exists because ritonavir dramatically increases the amount of sildenafil in the bloodstream, raising the risk of serious adverse effects.

What the Source Says

The interaction between ritonavir and sildenafil is documented in the official FDA-approved labeling for sildenafil. The source record classifies this combination as contraindicated—the highest level of caution in drug interaction guidance.

According to the FDA label:

• Ritonavir is a strong inhibitor of an enzyme called CYP3A4, which the body uses to break down and clear sildenafil from the bloodstream.
• When ritonavir and sildenafil are used together, sildenafil exposure increases approximately 11-fold (measured as AUC, or area under the concentration-time curve)—meaning 11 times more drug circulates in the body compared to when sildenafil is used alone.
• The FDA-approved dosing instruction is explicit: Do not exceed a maximum single dose of 25 mg in a 48-hour period if ritonavir must be used concurrently.
• This dramatic increase in sildenafil levels can potentiate (enhance) dangerous drops in blood pressure, particularly if sildenafil is combined with other blood-pressure-lowering medications.

The source material is the sildenafil citrate FDA drug label, specifically sections addressing CYP3A4 inhibitors and ritonavir interactions (sections 2.4, 5.6, and 7.4).

How to Understand This

What Is CYP3A4 and Why Does It Matter?

CYP3A4 is an enzyme in the liver responsible for metabolizing (breaking down) many drugs, including sildenafil. When a medication works as a CYP3A4 inhibitor, it blocks or slows this enzyme's activity, which means drugs that depend on CYP3A4 for clearance accumulate in the body to higher levels than expected.

Ritonavir is a protease inhibitor—a class of antiretroviral medication used to treat HIV. One of ritonavir's most significant pharmacological properties is that it is a potent (strong) CYP3A4 inhibitor. This is actually why ritonavir is sometimes used in low doses as a "booster" in HIV regimens—to increase the levels of other antiretroviral drugs. However, this same mechanism creates a major risk when ritonavir is combined with sildenafil.

The 11-Fold Increase in Sildenafil Levels

The FDA label documents a clinical observation: co-administration of ritonavir increased the systemic exposure of sildenafil 11-fold. In plain language, this means that when a person taking ritonavir takes a standard sildenafil dose, the amount of sildenafil circulating in the bloodstream and available to act on the body is roughly 11 times higher than it would be without ritonavir.

This is a dramatic increase. A standard sildenafil dose for erectile dysfunction is 50 mg, but when combined with ritonavir, that dose would produce blood levels equivalent to taking 550 mg without ritonavir. This excess exposure raises the risk of dose-related side effects, including severe hypotension (dangerously low blood pressure), visual disturbances, priapism (a prolonged, painful erection), and syncope (fainting).

Why Blood Pressure Matters in This Interaction

Sildenafil works by relaxing blood vessels and lowering blood pressure as a side effect of its intended action on erectile tissue. The FDA label notes that sildenafil can potentiate (enhance) the hypotensive effects of other medications that lower blood pressure, including nitrates, alpha blockers, and antihypertensives. When sildenafil levels are 11 times higher due to ritonavir, this blood-pressure-lowering effect is magnified, creating a serious risk of symptomatic hypotension (dizziness, fainting, heart attack, or stroke).

Important note: The FDA label explicitly states that sildenafil is contraindicated (absolutely should not be used) with nitrates—organic nitric oxide donors—because the combined blood-pressure-lowering effects can be life-threatening. If a patient on ritonavir is also taking certain cardiac or blood-pressure medications, the interaction risk increases further.

Mechanism: What the Source Does and Does Not Say

The supplied FDA source record does not specify a mechanistic explanation (e.g., no statement like "ritonavir inhibits the CYP3A4 metabolism of sildenafil"). However, the FDA label does identify ritonavir as a strong CYP3A4 inhibitor and documents the 11-fold increase in sildenafil AUC. This is the documented clinical evidence: the combination produces a measurable, dramatic increase in sildenafil exposure. The practical consequence—strict dose limitation—flows from that observation.

Who Should Pay Particular Attention

Anyone taking ritonavir who is considering or currently taking sildenafil should treat this as a high-priority discussion with their pharmacist or physician. This includes:

• People living with HIV on ritonavir-containing antiretroviral regimens who have erectile dysfunction.
• Patients on ritonavir who take sildenafil for pulmonary hypertension (a different indication, sold under the brand name Revatio).
• Anyone on ritonavir also taking blood-pressure medications, as the interaction risk compounds.
• Patients with a history of cardiovascular disease, as sildenafil-induced hypotension could be particularly dangerous.

In general, the FDA classification of this combination as contraindicated means that most healthcare providers will avoid it entirely. Only under specialized circumstances—for instance, when no alternative is available and the benefit clearly outweighs the risk—might a provider consider the combination with the strict 25 mg / 48-hour dosing limit.

Hypothetical Examples

Example 1: Standard vs. Restricted Dosing

This is a hypothetical illustration of the documented dose restriction.

A person without ritonavir taking sildenafil for erectile dysfunction might receive a typical starting dose of 50 mg. A person on ritonavir cannot safely take 50 mg; the FDA label requires starting at no more than 25 mg, and that dose cannot be repeated within 48 hours. This reflects the 11-fold increase in systemic exposure—a 25 mg dose on ritonavir produces blood levels closer to a 275 mg dose without the drug interaction, approaching the threshold for serious adverse effects.

Example 2: Compounded Risk With Other Medications

This is a hypothetical scenario illustrating the blood-pressure interaction documented in the FDA label.

Imagine a patient on ritonavir who also takes an alpha blocker (a blood-pressure medication). The FDA label warns that sildenafil potentiates the hypotensive effects of alpha blockers. If this patient took even a restricted 25 mg sildenafil dose with ritonavir, the combined blood-pressure-lowering effects of all three drugs could cause symptomatic hypotension—dizziness, fainting, or worse. This is why medication review with a pharmacist is essential before any sildenafil use in a patient on ritonavir.

What to Discuss With a Pharmacist or Physician

If you are on ritonavir and considering sildenafil, or if you are already taking both, bring these questions and points to your pharmacist or physician:

• Is this combination medically necessary for me? The FDA classifies it as contraindicated, so the first conversation should explore whether an alternative exists (e.g., a different antiretroviral regimen without ritonavir, or a different approach to erectile dysfunction or pulmonary hypertension).
• What other medications am I taking that lower blood pressure? Provide a complete list of all prescription medications, over-the-counter drugs, and supplements. Alpha blockers, nitrates, and many blood-pressure medications interact with sildenafil; ritonavir magnifies that risk.
• If the combination is necessary, what dose and frequency are safe for me? The FDA label specifies no more than 25 mg in a 48-hour period, but your healthcare provider may recommend even stricter limits based on your individual situation.
• What warning signs should I watch for? Ask about symptoms of dangerous low blood pressure (severe dizziness, fainting, chest pain) or priapism (painful erection lasting more than 4 hours), and when to seek emergency help.
• How will my healthcare team monitor me? If the combination is used, ask about blood pressure monitoring, follow-up visits, and any lab work relevant to your HIV care and overall cardiovascular health.
• Are there any new antiretroviral options? Modern HIV treatment includes many alternatives to ritonavir. If you are on ritonavir-containing therapy, discuss with your HIV specialist whether newer regimens might be suitable, which could eliminate this interaction.

Do not start, stop, skip, or change the dose of either medication on your own. These decisions must involve your healthcare provider and pharmacist.

Key Takeaways

• Ritonavir and sildenafil are listed as a contraindicated combination by the FDA, meaning the risks generally outweigh the benefits.
• Ritonavir is a strong CYP3A4 inhibitor that blocks the breakdown of sildenafil, causing sildenafil blood levels to increase approximately 11-fold.
• If the combination must be used, the maximum dose is 25 mg of sildenafil as a single dose, with no more than one dose in a 48-hour period—far below standard dosing.
• The primary risk is dangerous drops in blood pressure, especially if other blood-pressure-lowering medications are also being taken.
• Anyone on ritonavir considering sildenafil should discuss alternatives with their HIV specialist and pharmacist, as safer options may be available.

Sources

• Daily Med (National Library of Medicine) – Search for sildenafil citrate to access the complete FDA-approved drug label, including sections on CYP3A4 inhibitors and ritonavir interactions.
• OpenFDA – A public database of FDA drug labeling data, searchable by drug name and interaction type.
• PubMed (National Library of Medicine) – Use for peer-reviewed clinical research on protease inhibitors, CYP3A4 interactions, and sildenafil pharmacokinetics.
• RxNorm (National Library of Medicine) – A standardized nomenclature for clinical drugs, useful for identifying generic and brand names.
• AIDSinfo (National Institutes of Health) – Official U.S. government resource for HIV treatment and drug interactions, including protease inhibitors and antiretroviral combinations.

Next Steps

If you are taking ritonavir, sildenafil, or both, visit checkdruginteractions.com to check your complete medication list for documented interactions. Enter all your prescription drugs, over-the-counter medications, and supplements to get a comprehensive interaction report. Then confirm any medication decisions—especially decisions about starting, stopping, or changing doses—with your pharmacist or physician. Your healthcare team has your full medical history and can weigh the specific risks and benefits for your situation.